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Objective: Oligometastatic prostate cancer is a limited metastatic disease state in which
potential long-term control is still possible with the use of targeted therapies such as
surgery or stereotactic body radiation therapy (SBRT). SBRT may as well potentially
prolong the time before the initiation of androgen deprivation therapy (ADT) and docetaxel
chemotherapy for oligometastatic prostate cancer. The goal of this study is to outline
prognostic factors associated with improved outcome with SBRT for metastatic prostate
cancer and to quantify the effect of prior systemic treatments such as ADT and docetaxel
on survival after SBRT.
Methods: Twenty-four prostate cancer patients were treated with SBRT at the Philadel-
phia CyberKnife Center between August 2007 and April 2014. Retrospective data
collection and analysis were performed for these patients on this Institutional Review
Board approved study. Kaplan–Meier methodology was utilized to estimate and visually
assess overall survival (OS) at the patient level, with comparisons accomplished using the
log-rank test. Unadjusted hazard ratios were estimated using Cox proportional hazards
regression modeling.
Results: An improved median survival was noted for patients with oligometastatic
disease defined as4 lesions with median survival of >3 years compared with 11months
for polymetastases (p=0.02). The use of docetaxel at some time in follow-up either before
or after SBRT was associated with decreased survival with median survival of 9months
vs. >3 years (p=0.01).
Conclusion: Prognosis was better for men with recurrent prostate cancer treated
with SBRT if they had 4 metastases (oligometastases) or if docetaxel was not
necessary for salvage treatment. The prolonged median OS for men with oligometas-
tases in this population of heavily pretreated prostate cancer patients following SBRT
may allow for improved quality of life because of a delay of more toxic salvage
therapies.
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Introduction
According to recent reporting by the National Cancer Institute,
15% of men will be diagnosed with prostate cancer in their
lifetime (1). In 2011, there were around 2.7 million men living
with prostate cancer in the United States alone. If at the time
of diagnosis, disease is confined to the prostate gland and sur-
rounding lymph nodes, the 5-year survival rate approaches 100%;
but if distant metastases are present, this rate falls to 28% (1).
However, metastatic lesions are not all alike. In 1995, Hellman
and Weichselbaum first proposed the idea of oligometastatic
cancer, an intermediate state on a spectrum between localized
and widespread cancer. By definition, oligometastatic cancer is
a disease state in which long-term control is still possible (2).
The epitomization of this is seen in liver metastasis from pri-
mary colon cancers and lung metastasis from sarcoma because
resecting these lesions can be curative. Today, oligometastatic
cancers are identified as having a unique biological profile, one
that limits its metastatic potential. In this context, the use of
targeted therapies, such as stereotactic body radiation therapy
(SBRT), may serve to control further spread of the disease (3).
Efforts have been made to combine SBRT with systemic therapies
when there is only a limited extent of metastasis, but the con-
tribution of this strategy to progression free survival or overall
survival (OS)is yet to be determined for any particular cancer
type (4).
Androgen deprivation therapy (ADT) is the mainstay of treat-
ment for recurrent/metastatic prostate cancer after local therapy,
and this therapy is associated with significant decreases in sexual
quality of life, increased risk of skeletal fractures, cardiovascular-
related mortality, and insulin resistance (5, 6). Efforts have been
made to reduce the overall use of ADT, and intermittent ADT
have shown similar efficacy for disease control when compared
with continuous ADT (7). Recent preliminary data suggests the
use of SBRT in salvage therapy for metastatic disease is an
effective means for preventing biochemical relapse (8). Bhat-
tasali et al. suggests that castrate-resistant clones are present early
in metastatic disease; hence, SBRT therapy for oligometastatic
lesions may serve to delay disease progression (9). Berkovic and
colleagues’ recent publication suggests that SBRT utilization for
prostate oligometastasis delayed the use of palliative ADT by a
median of 38months in a group of 24 patients (10). Decaestecker
et al. also recently published similar results (11). Currently, the
“Surveillance or metastasis-directed Therapy for OligoMetastatic
Prostate cancer recurrence (STOMP),” designed to assess the
efficacy of SBRT or surgery for controlling oligometastatic dis-
ease (12), is in phase II clinical trials. The primary goal of
this trial is to prolong the time before the initiation of pal-
liative ADT, and one endpoint of this study is ADT-free sur-
vival.
Docetaxel is themainstay therapy for castrate-resistant prostate
cancer. The S9916 trial reported docetaxel as a second-line agent
that could improve OS (13). However, in this trial, the median
time to progression in patients receiving docetaxel was only
6.3months and the OS was 17.5months (13). The TAX 327
trial reported median survival of patients with castrate-resistant
prostate cancer of 19.2months when treated with docetaxel (14).
Currently, a variety of therapies have been implemented in a post-
docetaxel setting with modest successes (15). To our knowledge,
no publications address the contribution of SBRT to OS after
docetaxel therapy. The goal of this study is to outline prog-
nostic factors associated with improved outcome with SBRT for
metastatic prostate cancer and to quantify the effect of prior




Twenty-four prostate cancer patients were treated with SBRT
at the Philadelphia CyberKnife Center between August 2007
and April 2014. Retrospective data collection and analysis were
performed for these patients. The Institutional Review Board
(IRB) of the Crozer Keystone Health System granted approval for
this study. Eligibility for inclusion in this study was the previ-
ous biopsy-proven diagnosis of prostate cancer and the previous
treatment of the disease. Confirmation of prostate metastasis
was provided using biopsy (n= 8), magnetic resonance imaging
(MRI, n= 7), positron emission tomography/computed tomog-
raphy (PET/CT, n= 3), or CT alone (n= 6). Metastatic workup
included the use of a (99m)Tc-methylene (MDP) bone scan,
PET/CT, CT, MRI, or both CT and MRI. All patients had pro-
gression of prostate cancer documented by rising PSA.
Treatment
Stereotactic body radiation therapy with 6 mV photons was
administered using the CyberKnife system (Accuray Incorpo-
rated, Sunnyvale, CA, USA). CT was obtained for treatment plan-
ning, which was performed usingMultiplan software. Contouring
of metastases or adenopathy (CTV) and organs at risk (OAR)
in proximity was performed. Dose constraints for normal tissues
were previously described by Timmerman and were implemented
for OAR (16). The gross target volume (GTV) was equal to the
clinical target volume (CTV), and a uniform 5mm CTV expan-
sion was added for planning target volumes (PTVs). At times,
margins were reduced to 3mm when needed for proximal nor-
mal tissues. Local failure is defined as recurrence within the CTV.
Dose was prescribed to the 60–80% isodose line to cover 95% of
the PTVs with the prescribed dose. Tracking was performed using
6D Skull or Xsight Spine or with fiducial markers if necessary, and
synchrony tracking was performed as warranted by the treatment
site on a case-by-case basis. Treatment delivery was accomplished
with between 80 and 150 beams and tracking images were taken
every three beams.
Statistics
Descriptive statistics were used to describe the study popula-
tion. Recurrence patterns are recorded after first course of SBRT.
Kaplan–Meier methodology was utilized to estimate and visu-
ally assess OS at the patient level from first course of SBRT
for oligometastases. The log-rank statistic was used to compare
survival profiles by ADT and docetaxel treatments, in addition
to the following measures: age dichotomized at 65 years, PSA
decline after SBRT, CTV volume (cut at median CTV for all
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metastasis), Gleason score, lymph node or other site metastasis,
and oligometastatic (4 lesions) vs. polymetastatic disease. Cox
proportional hazards modeling was used to estimate unadjusted
hazard ratios (HRs). As power was limited because of a small sam-
ple size, adjusted multivariable Cox proportional hazard models
were not estimated. For all unadjusted models, a p-value of<0.05
was considered as statistically significant.
Results
Patients
The median age of patients at the time of SBRT therapy was
69 years (53–88). A majority of our patients had Gleason scores of
8 at the time of diagnosis (n= 13). The majority of our patients
were initially treated with intensity-modulated radiation therapy
(IMRT) for prostate cancer at the time of diagnosis (n= 11).
Five patients underwent a prostatectomy, four patients were
treated with hormone and chemotherapy, two patients received
brachytherapy seed implants, one received SBRT, and another
cryotherapy. All patients had previously received ADT as part of
the initial treatment regimen, except one patient who had under-
gone prostatectomy. Nine of our patients had oligometastatic
disease, defined as having four or fewer lesions. Nearly all of the
patients were considered to have castrate-resistant cancer at the
time of SBRT (n= 20), and 15 patients had also progressed after
receiving docetaxel therapy. SBRT dose was based on lesion size
and location with the median dose of 24 Gy (18–50) received in
three to five fractions. The sites of treatment included bone and
lymphnode in themajority of patients. Five patients receivedmore
than one course of SBRT after at least 1month from the initial
treatment start date. In total 39 sites were treatedwith SBRT in this
patient cohort. The median CTV was 21.9 cm3. Less than half of
the sites that received SBRT had previous external beam radiation
to the SBRT site. A summary of all patient and treatment baseline
characteristics at diagnosis, at SBRT, and after SBRT is given in
Table 1. The vast majority of patients had no adverse reaction
to the treatment. One patient experienced grade 1 diarrhea and
another patient reported grade 2 pelvic pain.
Survival
Gleason score, CTV, previous radiation to CTV, decrease in PSA,
and age were not associated with OS after SBRT in our analysis
on the basis of the log-rank statistic and Kaplan Meier estimates
(p= 0.76, 0.36, 0.28, 0.29, and 0.25, respectively). Although not
statistically significant, there was a trend for enhanced survival
in patients that had metastases in lymph node sites vs. any other
site (p= 0.15, data not shown). A decrease in PSA after SBRT
was not a prognostic indicator for OS. Of the 15 patients who
had follow-up PSA after SBRT, nine had decrease in PSA. PSA,
however, was useful to track progression of disease and guided
further metastatic workup.
An improved median survival was noted for patients with
oligometastatic disease with median survival >3 years com-
pared with 11months for polymetastases (log-rank p= 0.0198,
Figure 1).
The use of docetaxel at some time in follow-up either before
or after SBRT was associated with decrease in median survival of












Treatment modality, n (%)
Primary IMRT 11 (45.8)
Primary prostatectomy 5 (20.8)
Hormone and chemotherapy 4 (16.7)
Seed brachytherapy 2 (8.3)
Cryotherapy 1 (4.2)
SBRT 1 (4.2)
Time initial diagnosis to SBRT (mo)
Median 51
Range 2–229








Location of lesions, n (%)
Bone 15 (62.5)
Lymph node 7 (29.2)
CNS 1 (4.2)
Lung 1 (4.2)






Previous radiation to SBRT site, n (%) 10 (41.7)
Systemic treatment, n (%)
None or not ADT refractory 4 (16.7)
ADT refractory 5 (20.8)







Local (in SBRT field) 1 (4.2)
Distant (out of SBRT field) 12 (50.0)
9months when docetaxel was used vs. >3 years with no use (log-
rank p= 0.0115, Figure 2A). This effect persists when evaluating
only patients with castrate-resistant disease withmedian survivals
of 9months vs. >3 years (log-rank p= 0.0117, Figure 2B). In
contrast, there was no significant survival difference between
patients that received ADT when compared with those who did
not (log-rank p= 0.936).
Overall survival after SBRT in all patients was assessed, and the
median time until death was 13months. A small subset of patients
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died within 3months after receiving SBRT. When these patients
were excluded from this analysis, the median survival time after
SBRT was 31months (Figure 3).
Tables 2 and 3 provides results for univariate Cox proportional
hazard regression modeling for all patients and those surviving
>3months after SBRT to reduce bias for patients who were at
end of life and treated palliatively. The hazard of death is sig-
nificantly increased among those with more than four metastatic
lesions (HR 3.33, p= 0.057; HR 6.52, p= 0.048) and treatment
with docetaxel (HR 4.16 p= 0.027; HR 4.34 p= 0.069).
At the conclusion of our study, we had nine patients who
never received docetaxel with a median survival time from first
treatment with SBRT of 41months (11–70).We had three patients
who did not receive palliative ADT 32, 40, and 70months follow-
ing first SBRT treatment. Overall 25% of patients remain free of
disease at last follow-up.
Discussion
In this retrospective study, we report our experience in men
with metastatic prostate cancer who were treated with SBRT.
FIGURE 1 | Survival by number of metastatic lesions: oligometastases
vs. polymetastases.
FIGURE 2 | (A) Survival by use of docetaxel chemotherapy: yes vs. no. (B) Survival by use of docetaxel with ADT refractory: yes vs. no.
Our findings support previous descriptions of the oligometastatic
state of prostate cancer. In our experience, those patients with
oligometastatic disease treated with SBRT had significantly longer
OS times than those that hadmore than four lesions. This supports
other work that suggests that for patients with four or fewer
metastatic lesions, targeted therapy, such as SBRT, is an effective
means to control disease. Currently, the NRG-BR001 trial aims
to more clearly define the dose parameters and side effects of
SBRT for oligometastatic disease and includesmenwith a prostate
cancer primary.
Surprisingly, higher Gleason score was not associated with
worse survival after SBRT. Recently published data by Rusthoven
et al. demonstrated that higher Gleason scores are a strong pre-
dictor of decreased OS in patients with metastatic prostate cancer
(17). One possible explanation for this discrepancy is that our
group was heavily pretreated and not only castrate resistant but
FIGURE 3 | Overall survival entire group vs. overall survival for
patient’s surviving at least 3months.
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TABLE 2 | Univariate Cox regression model results for all patients.
Hazard
ratio
Lower CL Upper CL Prob
ChiSq
ADT+ docetaxel received 4:891 0:803 29:785 0:0851
ADT refractory, no docetaxel 1:038 0:123 8:781 0:9726
PSA increased 1:85 0:412 8:305 0:4221
Previous RT in SBRT field 1:432 0:53 3:873 0:479
Age <65 years 1:764 0:657 4:738 0:2599
CTV>22 1:578 0:573 4:349 0:3778
Gleason score>7 1:197 0:368 3:898 0:7648
ADT untreated 2:84 0:498 16:19 0:24
Non-lymph node site 3:009 0:869 10:412 0:082
Polymetastatic disease 3:328 0:966 11:473 0:0568
Docetaxel received 4:162 1:174 14:751 0:0272




Lower CL Upper CL Prob
ChiSq
ADT+docetaxel received 11:508 0:501 264:091 0:1265
ADT refractory, no docetaxel 3:239 0:119 88:286 0:4859
PSA increased 1:982 0:191 20:608 0:567
Previous RT in SBRT field 3:308 0:826 13:245 0:0909
Age <65 years 2:254 0:596 8:528 0:2312
CTV >22 3:15 0:69 14:374 0:1384
Gleason score >7 1:341 0:261 6:897 0:7257
ADT untreated 6:467 0:318 131:363 0:2243
Non-lymph node site 5:975 0:925 38:582 0:0603
Polymetastatic disease 6:519 1:016 41:816 0:048
Docetaxel received 4:338 0:889 21:164 0:0696
also docetaxel resistant which may lead to a more homogeneous
high risk population at the time of SBRT with little prognostic
value from the Gleason score at initial diagnosis.
Androgen deprivation therapy and docetaxel treatment are
standard systemic treatments for metastatic prostate cancer. In
our study, we identified two patients with oligometastatic disease
who were treated with SBRT and had not yet received palliative
ADT. One such patient was treated with SBRT without ADT or
docetaxel on three separate occasions over a period of 3 years with
no evidence of disease at last follow-up by diagnostic studies and
PSA.
In our experience, those patients treated with docetaxel at
any time had decreased survival compared with those who had
not received this treatment. When evaluating only patients with
castrate-resistant disease, we still found that those who had
received docetaxel fared worse than those who had not. Consider-
ing docetaxel as a second-line agent, it follows that these patients
have more advanced disease, which could account for the dimin-
ished survival times. However, recent work by Sweeney et al (18).
suggests that upfront docetaxel with ADT enhances OS in patients
with visceral metastases and/or four or more bone metastases
vs. ADT alone (18). We consider our cohort of patients distinct
from those treated upfront with docetaxel and ADT, because our
patients only received docetaxel as a palliative measure. More
work is needed to determine the effect of SBRT in patients treated
upfront with docetaxel and ADT, especially in those patients with
oligometastatic visceral metastases. Of note, nine of our patients
who were treated with SBRT have yet to require docetaxel as a
second-line agent. Such end points may speak to the ability of
SBRT to improve quality of life in patients with oligometastatic
prostate cancer by promoting a longer interval to salvage systemic
therapy especially given the low rates of SBRT-related toxicity
reported herein.
In all patients who had received SBRT therapy, median OS
was 13months. Owing to the palliative nature of some SBRT
treatments, several of our patients were treated at the end of life.
When these patients were removed, the median survival time
increased to 31months, which compares favorably with second-
line chemotherapy trials.
Conclusion
Prognosis was better for men with recurrent prostate cancer
treated with SBRT if they had four or less metastases (oligometas-
tases) or if they had not required docetaxel treatment. Use of
SBRT for oligometastases is an area of active research to hope-
fully improve quality of life and survival for men with metastatic
prostate cancer.
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